Gilbert W. Gleim

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

40h-index8.1kcitations166works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cardiovascular and exercise physiology(35), Sports injuries and prevention(31), Sports Performance and Training(30), Muscle activation and electromyography studies(21), Blood Pressure and Hypertension Studies(18)

Publications166 total

Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials
Journal of clinical lipidology·2015· 12 cited
Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome
Pediatric Nephrology·2012· 47 cited
Comparison of the Intrinsic Vasorelaxant and Inotropic Effects of the Antiarrhythmic Agents Vernakalant and Flecainide in Human Isolated Vascular and Cardiac Tissues
Journal of Cardiovascular Pharmacology·2012· 10 cited
Losartan and enalapril are comparable in reducing proteinuria in children
Kidney International·2012· 41 cited
Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia
Journal of clinical lipidology·2011· 13 cited
Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial
Nephrology Dialysis Transplantation·2011· 62 cited
Randomized, Double-Blind, Controlled Study of Losartan in Children with Proteinuria
Clinical Journal of the American Society of Nephrology·2010· 56 citedOpen Access
Assessment of the use of angiotensin receptor blockers in major European markets among paediatric population for treating essential hypertension
Journal of Human Hypertension·2008· 10 citedOpen Access
LIPID-ALTERING EFFICACY AND SAFETY PROFILE OF CO-ADMINISTERED EXTENDED RELEASE NIACIN/LAROPIPRANT AND SIMVASTATIN IN PATIENTS WITH DYSLIPIDEMIA
Atherosclerosis Supplements·2008· 2 cited
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy:Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
University of Groningen research database (University of Groningen / Centre for Information Technology)·2007
The effect of baseline physical activity on cardiovascular outcomes and new‐onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study
Journal of Internal Medicine·2007· 42 citedOpen Access
Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy
Journal of the American Society of Nephrology·2007· 299 cited
A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension
Clinical Therapeutics·2006· 13 cited
Problem-based learning of research skills
Journal of Electrocardiology·2005· 32 cited
The Impact of Morbid Events on Survival Following Hospitalization for Complicated Myocardial Infarction
European Journal of Heart Failure·2005· 10 citedOpen Access
Importance of Baseline Distribution of Proteinuria in Renal Outcomes Trials: Lessons from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study
Journal of the American Society of Nephrology·2005· 39 cited
The LIFE Study
Hypertension·2005
Fixed-Dose Combinations in the Management of Hypertension
American Journal of Cardiovascular Drugs·2005· 52 cited
The LIFE sudy
2005
Contributors
Hypertension·2005
page 1 of 9Next →

Frequent Co-authors

Malachy P. McHugh(11), Timothy F. Tyler(11), Stephen Nicholas(11), James A. Nicholas(11), Malachy P. McHugh(5), Shahnaz Shahinfar(5), Declan Connolly(4), Roger Eston(4), Neil L. Coplan(4), Nicholas J.A. Webb(4), Chun Sing Lam(4), Thomas G. Wells(4), Timothy Roy(3), S. Peter Magnusson(3), Jusuf Zlatanic(3), Burton I. Korelitz(3), Nina S. Stachenfeld(3), Michael F. Michelis(3), Beth W. Glace(3), Zhongxin Zhang(2)